{"success":true,"data":{"pressRelease":{"id":"60895","rtpr_id":"nGNX531jhG","ticker":"4587","exchange":"TSE Tokyo","all_tickers":["4587"],"title":"Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan","author":"Globe Newswire","published_at":"2026-06-11T07:04:46.092Z","article_body":"* Completion of patient dosing in the registrational Phase 2 clinical trial\nfor (64)Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific\nmembrane antigen (PSMA) expressed on prostate cancer cells\n* Data analysis is now underway to support future regulatory submission in\nJapan\nBOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Curium Group announced today that\ntogether with PeptiDream Inc. and PDRadiopharma Inc., patient dosing has been\ncompleted in the registrational Phase 2 clinical trial for (64)Cu-PSMA-I&T in\nJapan.\n\n(64)Cu-PSMA-I&T is a PET radiopharmaceutical targeting PSMA. (64)Cu-PSMA-I&T\nis being assessed as a PET agent labeled with the radioisotope Copper-64. The\ntrial is conducted under the strategic collaboration between PDRadiopharma, a\nwholly owned subsidiary of PeptiDream, and Curium, aiming at advancing\ninnovative diagnostic radiopharmaceuticals for prostate cancer in Japan.\n\nThe open-label, single-arm Phase 2 study is designed to evaluate the\nsensitivity, specificity, and safety of (64)Cu-PSMA-I&T in Japanese patients\nnewly diagnosed with unfavorable intermediate, high or very high-risk prostate\ncancer and are scheduled for prostatectomy with pelvic lymph node dissection.\nThe results from this study, together with data from Curium’s ongoing global\nclinical trials, are expected to support future regulatory submission in\nJapan.\n\nIn parallel, Curium announced in February, a registrational clinical trial of\nthe therapeutic counterpart, (177)Lu-PSMA-I&T, is being advanced to evaluate\nits efficacy and safety in patients with metastatic castration-resistant\nprostate cancer (mCRPC), as part of a theranostic approach.\n\nRenaud Dehareng, CEO of Curium Group commented: “Conducting these trials, in\npartnership with PeptiDream and PDRadiopharma, marks a significant milestone\nin our mission to expand access to cutting-edge radiopharmaceuticals to\npatients with prostate cancer across Asia. By combining Curium’s global\ndevelopment expertise with PDRadiopharma’s deep local knowledge and\ninfrastructure, we are well-positioned to deliver transformative solutions to\npatients with prostate cancer in Japan.”\n\nPatrick C. Reid, President & CEO of PeptiDream commented: “The completion of\npatient dosing marks an important milestone in the development of\n(64)Cu-PSMA-I&T in Japan. This program represents a key component of our\ngrowing radiopharmaceutical pipeline and our broader theranostics strategy. We\nwould like to thank the patients, investigators and clinical sites for their\nparticipation and support.”\n\nAbout Prostate Cancer\n\nProstate cancer continues to be widely prevalent in Japan. Annually, there are\napproximately 90,000 – 100,000 new cases (*1). *1: National Cancer Center\nJapan\n\nClinical trial progress\n\nPhase 3 ECLIPSE trial - (177)Lu-PSMA-I&T, a PSMA-targeting ligand conjugated\nwith the radioisotope Lutetium-177, has been tested by Curium in a global\npivotal Phase 3 ECLIPSE trial (ClinicalTrials.gov\n(https://www.globenewswire.com/Tracker?data=ZqC3WuMnSWnAqMpggZnPtbHTmg9HEgGUwiDVHFL3HcX72-wxdfo9FjdS-X4i1esXuZrTYjf-x5uvBxjNd5p7yiwYn6DvIxQMd7cyLPg1jT6ZPXis_7b015fQsW3_KOvr)\nidentifier; NCT05204927). It reported that the primary endpoint was met,\ndemonstrating a statistically significant and clinically meaningful benefit\nfor patients with mCRPC.\n\nPhase 3 SOLAR RECUR and SOLAR STAGE trial - (64)Cu-PSMA-I&T trials are being\nconducted to diagnose biochemical recurrence of prostate cancer (SOLAR RECUR\ntrial, NCT06235099) and for men newly diagnosed with unfavorable intermediate\nto very high-risk prostate cancer, electing to undergo surgery (SOLAR STAGE\ntrial, NCT06235151). The first in human Phase 1/2 SOLAR trial met the\nco-primary endpoints of region-level correct localization rate and\npatient-level correct detection rate in patients with histologically-proven\nprostate cancer.  \n\nPartnership Details\n\nUnder the terms of the partnership, Curium and PDRadiopharma will jointly\ncollaborate on clinical development activities of (64)Cu-PSMA-I&T and\n(177)Lu-PSMA-I&T and in Japan, with PDRadiopharma leading regulatory filing,\nmanufacturing, commercialization, and distribution activities in Japan. Curium\nwill continue to lead global development of the two agents and support\nPDRadiopharma through technology transfer to support the set-up of\nmanufacturing lines in Japan – including a high throughput Copper 64\nmanufacturing line based on Curium’s proprietary technology.\n\nAbout Curium\n\nCurium Pharma is a leading global radiopharmaceutical company with proven\nexpertise in the development, manufacturing and supply of radiopharmaceuticals\nthat transform the way cancer is diagnosed and treated. Headquartered in\nBoston with offices around the world, Curium’s mission is to find new and\nbetter ways to diagnose and treat cancer.\n\nWith a global footprint that extends to more than 70 countries, a skilled and\ndedicated team of over 5,000 employees, and four manufacturing sites, Curium\nis uniquely qualified to meet the significant supply and distribution of\nestablished products that underlie success in the radiopharmaceuticals market.\nCurium’s global leadership is embodied in a diverse and extensive portfolio\nof over 45 products, that advance patient care for a wide range of cancers.\n\nCurium’s pioneering legacy in nuclear medicine is the foundation of the\ncompany’s dedication to innovation and portfolio expansion to cancer\ntherapeutics, particularly in neuroendocrine tumors and with a late-stage\npipeline exploring opportunities in prostate cancer.\n\nTo learn more, visit www.curiumpharma.com.\n\nAbout PeptiDream Inc.\n\nPeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the\ntranslation of macrocyclic peptides into a whole new class of innovative\nmedicines to address unmet medical needs and improve the quality of life of\npatients worldwide. In its radiopharmaceutical business, through its\nwholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number\nof approved radiopharmaceuticals and radiodiagnostics in Japan, as well as\nleveraging its proprietary Peptide Discovery Platform System (PDPS) technology\nto discover and develop a deep pipeline of innovative targeted\nradiotherapeutics and radiodiagnostics, spanning both wholly-owned internal\nprograms and globally partnered programs. In its non-radiopharmaceutical\nbusiness, PeptiDream is similarly leveraging PDPS to discover and develop a\nbroad and diverse pipeline of investigational peptide therapeutics, peptide\ndrug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an\nextensive global network of discovery and development partners. PeptiDream is\nheadquartered in Kawasaki, Japan. For more information about our company,\nscience and pipeline, please visit www.peptidream.com/en/\n\nAbout PDRadiopharma\n\nPDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been\nproviding high-quality radiopharmaceuticals through the research and\ndevelopment, manufacturing, regulatory and sales as a forerunner in the field\nin radiopharmaceuticals, since it started its business in 1968. PDRadiopharma\ncurrently markets 21 radiodiagnostic products (spanning both SPECT and PET\nproducts) and 8 radiotherapeutic products (3 product categories) in Japan.\nAdditionally, PDRadiopharma and PeptiDream are developing a broad pipeline of\nradiotherapeutics and radiodiagnostics for both the Japan and global markets.\nFor more information about PDRadiopharma, please visit\nwww.pdradiopharma.com/en/\n\nInquiries:\n\nCurium\nCamilla Campell\nVP, Head of Global Communications\nEmail: communications@curiumpharma.com\nWebsite: www.curiumpharma.com\n\nPeptiDream Inc.\nContact: Yuko Okimoto, IR & Corporate Communications\nEmail: info@peptidream.com\nWebsite: https://www.peptidream.com/en/\nX: https://x.com/PeptidreamInc\nLinkedIn: https://www.linkedin.com/company/peptidream\n\nPDRadiopharma Inc.\nContact: Noriko Tanaka, General Affairs \nEmail: s-info-hq@pdradiopharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/625b195f-19cf-4bc0-b31e-a307f90da31e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX531jhG","title":"Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan","author":"Globe Newswire","ticker":"4587","created":"2026-06-11T07:04:46.092Z","tickers":["4587"],"exchange":"TSE Tokyo","article_body":"* Completion of patient dosing in the registrational Phase 2 clinical trial\nfor (64)Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific\nmembrane antigen (PSMA) expressed on prostate cancer cells\n* Data analysis is now underway to support future regulatory submission in\nJapan\nBOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Curium Group announced today that\ntogether with PeptiDream Inc. and PDRadiopharma Inc., patient dosing has been\ncompleted in the registrational Phase 2 clinical trial for (64)Cu-PSMA-I&T in\nJapan.\n\n(64)Cu-PSMA-I&T is a PET radiopharmaceutical targeting PSMA. (64)Cu-PSMA-I&T\nis being assessed as a PET agent labeled with the radioisotope Copper-64. The\ntrial is conducted under the strategic collaboration between PDRadiopharma, a\nwholly owned subsidiary of PeptiDream, and Curium, aiming at advancing\ninnovative diagnostic radiopharmaceuticals for prostate cancer in Japan.\n\nThe open-label, single-arm Phase 2 study is designed to evaluate the\nsensitivity, specificity, and safety of (64)Cu-PSMA-I&T in Japanese patients\nnewly diagnosed with unfavorable intermediate, high or very high-risk prostate\ncancer and are scheduled for prostatectomy with pelvic lymph node dissection.\nThe results from this study, together with data from Curium’s ongoing global\nclinical trials, are expected to support future regulatory submission in\nJapan.\n\nIn parallel, Curium announced in February, a registrational clinical trial of\nthe therapeutic counterpart, (177)Lu-PSMA-I&T, is being advanced to evaluate\nits efficacy and safety in patients with metastatic castration-resistant\nprostate cancer (mCRPC), as part of a theranostic approach.\n\nRenaud Dehareng, CEO of Curium Group commented: “Conducting these trials, in\npartnership with PeptiDream and PDRadiopharma, marks a significant milestone\nin our mission to expand access to cutting-edge radiopharmaceuticals to\npatients with prostate cancer across Asia. By combining Curium’s global\ndevelopment expertise with PDRadiopharma’s deep local knowledge and\ninfrastructure, we are well-positioned to deliver transformative solutions to\npatients with prostate cancer in Japan.”\n\nPatrick C. Reid, President & CEO of PeptiDream commented: “The completion of\npatient dosing marks an important milestone in the development of\n(64)Cu-PSMA-I&T in Japan. This program represents a key component of our\ngrowing radiopharmaceutical pipeline and our broader theranostics strategy. We\nwould like to thank the patients, investigators and clinical sites for their\nparticipation and support.”\n\nAbout Prostate Cancer\n\nProstate cancer continues to be widely prevalent in Japan. Annually, there are\napproximately 90,000 – 100,000 new cases (*1). *1: National Cancer Center\nJapan\n\nClinical trial progress\n\nPhase 3 ECLIPSE trial - (177)Lu-PSMA-I&T, a PSMA-targeting ligand conjugated\nwith the radioisotope Lutetium-177, has been tested by Curium in a global\npivotal Phase 3 ECLIPSE trial (ClinicalTrials.gov\n(https://www.globenewswire.com/Tracker?data=ZqC3WuMnSWnAqMpggZnPtbHTmg9HEgGUwiDVHFL3HcX72-wxdfo9FjdS-X4i1esXuZrTYjf-x5uvBxjNd5p7yiwYn6DvIxQMd7cyLPg1jT6ZPXis_7b015fQsW3_KOvr)\nidentifier; NCT05204927). It reported that the primary endpoint was met,\ndemonstrating a statistically significant and clinically meaningful benefit\nfor patients with mCRPC.\n\nPhase 3 SOLAR RECUR and SOLAR STAGE trial - (64)Cu-PSMA-I&T trials are being\nconducted to diagnose biochemical recurrence of prostate cancer (SOLAR RECUR\ntrial, NCT06235099) and for men newly diagnosed with unfavorable intermediate\nto very high-risk prostate cancer, electing to undergo surgery (SOLAR STAGE\ntrial, NCT06235151). The first in human Phase 1/2 SOLAR trial met the\nco-primary endpoints of region-level correct localization rate and\npatient-level correct detection rate in patients with histologically-proven\nprostate cancer.  \n\nPartnership Details\n\nUnder the terms of the partnership, Curium and PDRadiopharma will jointly\ncollaborate on clinical development activities of (64)Cu-PSMA-I&T and\n(177)Lu-PSMA-I&T and in Japan, with PDRadiopharma leading regulatory filing,\nmanufacturing, commercialization, and distribution activities in Japan. Curium\nwill continue to lead global development of the two agents and support\nPDRadiopharma through technology transfer to support the set-up of\nmanufacturing lines in Japan – including a high throughput Copper 64\nmanufacturing line based on Curium’s proprietary technology.\n\nAbout Curium\n\nCurium Pharma is a leading global radiopharmaceutical company with proven\nexpertise in the development, manufacturing and supply of radiopharmaceuticals\nthat transform the way cancer is diagnosed and treated. Headquartered in\nBoston with offices around the world, Curium’s mission is to find new and\nbetter ways to diagnose and treat cancer.\n\nWith a global footprint that extends to more than 70 countries, a skilled and\ndedicated team of over 5,000 employees, and four manufacturing sites, Curium\nis uniquely qualified to meet the significant supply and distribution of\nestablished products that underlie success in the radiopharmaceuticals market.\nCurium’s global leadership is embodied in a diverse and extensive portfolio\nof over 45 products, that advance patient care for a wide range of cancers.\n\nCurium’s pioneering legacy in nuclear medicine is the foundation of the\ncompany’s dedication to innovation and portfolio expansion to cancer\ntherapeutics, particularly in neuroendocrine tumors and with a late-stage\npipeline exploring opportunities in prostate cancer.\n\nTo learn more, visit www.curiumpharma.com.\n\nAbout PeptiDream Inc.\n\nPeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the\ntranslation of macrocyclic peptides into a whole new class of innovative\nmedicines to address unmet medical needs and improve the quality of life of\npatients worldwide. In its radiopharmaceutical business, through its\nwholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number\nof approved radiopharmaceuticals and radiodiagnostics in Japan, as well as\nleveraging its proprietary Peptide Discovery Platform System (PDPS) technology\nto discover and develop a deep pipeline of innovative targeted\nradiotherapeutics and radiodiagnostics, spanning both wholly-owned internal\nprograms and globally partnered programs. In its non-radiopharmaceutical\nbusiness, PeptiDream is similarly leveraging PDPS to discover and develop a\nbroad and diverse pipeline of investigational peptide therapeutics, peptide\ndrug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an\nextensive global network of discovery and development partners. PeptiDream is\nheadquartered in Kawasaki, Japan. For more information about our company,\nscience and pipeline, please visit www.peptidream.com/en/\n\nAbout PDRadiopharma\n\nPDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been\nproviding high-quality radiopharmaceuticals through the research and\ndevelopment, manufacturing, regulatory and sales as a forerunner in the field\nin radiopharmaceuticals, since it started its business in 1968. PDRadiopharma\ncurrently markets 21 radiodiagnostic products (spanning both SPECT and PET\nproducts) and 8 radiotherapeutic products (3 product categories) in Japan.\nAdditionally, PDRadiopharma and PeptiDream are developing a broad pipeline of\nradiotherapeutics and radiodiagnostics for both the Japan and global markets.\nFor more information about PDRadiopharma, please visit\nwww.pdradiopharma.com/en/\n\nInquiries:\n\nCurium\nCamilla Campell\nVP, Head of Global Communications\nEmail: communications@curiumpharma.com\nWebsite: www.curiumpharma.com\n\nPeptiDream Inc.\nContact: Yuko Okimoto, IR & Corporate Communications\nEmail: info@peptidream.com\nWebsite: https://www.peptidream.com/en/\nX: https://x.com/PeptidreamInc\nLinkedIn: https://www.linkedin.com/company/peptidream\n\nPDRadiopharma Inc.\nContact: Noriko Tanaka, General Affairs \nEmail: s-info-hq@pdradiopharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/625b195f-19cf-4bc0-b31e-a307f90da31e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-11T07:04:46.129377338Z","server_sent_at_ms":1781161486129},"received_at":"2026-06-11T07:04:46.201Z","source_url":null},"analysis":{"id":"50320","press_release_id":"60895","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"PeptiDream, via its subsidiary PDRadiopharma, and partner Curium Group announced the completion of patient dosing in the registrational Phase 2 clinical trial for (64)Cu-PSMA-I&T in Japan.\n\nThe open-label, single-arm study evaluates the diagnostic agent in Japanese patients with high-risk prostate cancer scheduled for surgery, aiming to support future regulatory submission in the country.\n\nThis milestone reinforces PeptiDream’s theranostics strategy, complementing Curium’s global Phase 3 trials for the therapeutic counterpart (177)Lu-PSMA-I&T.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"PeptiDream advances key diagnostic asset in Japan with Phase 2 dosing complete, supporting future regulatory filing."},"keyFigures":{"drugName":"(64)Cu-PSMA-I&T","phaseOfTrial":"Phase 2","customDimensions":{"new_prostate_cancer_cases_japan":"90,000 – 100,000"}},"quotedText":"The completion of patient dosing marks an important milestone in the development of (64)Cu-PSMA-I&T in Japan. This program represents a key component of our growing radiopharmaceutical pipeline and our broader theranostics strategy.","namedEntities":{"people":[{"name":"Renaud Dehareng","role":"CEO of Curium Group"},{"name":"Patrick C. Reid","role":"President & CEO of PeptiDream"},{"name":"Camilla Campell","role":"VP, Head of Global Communications, Curium"},{"name":"Yuko Okimoto","role":"IR & Corporate Communications, PeptiDream"},{"name":"Noriko Tanaka","role":"General Affairs, PDRadiopharma"}],"products":["(64)Cu-PSMA-I&T","(177)Lu-PSMA-I&T","Peptide Discovery Platform System (PDPS)"],"companies":[{"name":"PeptiDream Inc.","ticker":"4587","relationship":"filer"},{"name":"Curium Group","relationship":"partner"},{"name":"PDRadiopharma Inc.","relationship":"subsidiary"},{"name":"National Cancer Center Japan","relationship":"data source"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Completion of patient dosing in a registrational Phase 2 trial is a significant development milestone for the diagnostic asset (64Cu-PSMA-I&T). It de-risks the program and supports future regulatory submission in Japan, a key market for PeptiDream. However, it is not a binary approval event or a Phase 3 readout, so it is scored below 5."},"tickerRelevance":{"others":[{"ticker":"CURM","relevance":"partner"}],"primary":"4587"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":["partnership"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"clinical_milestone","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"low"}},"event_type":"clinical_trial","event_type_secondary":["partnership"],"sentiment":"bullish","material_impact_score":3,"narrative":"PeptiDream, via its subsidiary PDRadiopharma, and partner Curium Group announced the completion of patient dosing in the registrational Phase 2 clinical trial for (64)Cu-PSMA-I&T in Japan.\n\nThe open-label, single-arm study evaluates the diagnostic agent in Japanese patients with high-risk prostate cancer scheduled for surgery, aiming to support future regulatory submission in the country.\n\nThis milestone reinforces PeptiDream’s theranostics strategy, complementing Curium’s global Phase 3 trials for the therapeutic counterpart (177)Lu-PSMA-I&T.","key_figures":{"drugName":"(64)Cu-PSMA-I&T","phaseOfTrial":"Phase 2","customDimensions":{"new_prostate_cancer_cases_japan":"90,000 – 100,000"}},"named_entities":{"people":[{"name":"Renaud Dehareng","role":"CEO of Curium Group"},{"name":"Patrick C. Reid","role":"President & CEO of PeptiDream"},{"name":"Camilla Campell","role":"VP, Head of Global Communications, Curium"},{"name":"Yuko Okimoto","role":"IR & Corporate Communications, PeptiDream"},{"name":"Noriko Tanaka","role":"General Affairs, PDRadiopharma"}],"products":["(64)Cu-PSMA-I&T","(177)Lu-PSMA-I&T","Peptide Discovery Platform System (PDPS)"],"companies":[{"name":"PeptiDream Inc.","ticker":"4587","relationship":"filer"},{"name":"Curium Group","relationship":"partner"},{"name":"PDRadiopharma Inc.","relationship":"subsidiary"},{"name":"National Cancer Center Japan","relationship":"data source"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-11T07:05:02.943Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap","eventGravity":"clinical_milestone","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"low"}},"durationMs":null,"modelName":"george-droid-qwen-72b"}}